GlassScriptPhysician profile
Lori C Lebow
NPI 1376652883
$9,754.29
in general payments reported to CMS, 2019-2025
26 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,143 · 2020: $1,055 · 2021: $1,299 · 2022: $1,218 · 2023: $1,549 · 2024: $1,552 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,004 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,003.96 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,433.63 | 2019-2025 | Cequa |
| Alcon Vision LLC | $2,169.59 | 2019-2025 | Clareon, Unity, Voyager Dslt |
| Eyevance Pharmaceuticals LLC | $602.70 | 2019-2021 | |
| Lensar, INC. | $592.87 | 2023-2024 | Lensar Laser System |
| Abbvie INC. | $504.21 | 2022-2025 | |
| Allergan, INC. | $398.72 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $384.56 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $325.68 | 2022-2025 | Miebo, Stellaris, Envista Envy Iol |
| Glaukos Corporation | $307.01 | 2021-2025 | Idosetr, Photrexa Viscous and Photrexa |
| Oyster Point Pharma, INC. | $263.65 | 2022-2025 | Tyrvaya |
| Tearlab Corp | $242.86 | 2023 | Tearlab Osmolarity System |
| Dompe US, INC. | $226.04 | 2019-2025 | Oxervate |
| Sight Sciences, INC. | $213.38 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $168.09 | 2022-2024 | Tecnis Iol |
| Biotissue Holdings INC. | $167.76 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $141.01 | 2022-2023 | Iolmaster 700 |
| New World Medical,INC. | $132.28 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $117.94 | 2022-2025 | Acthar |
| Bausch Health US, LLC | $102.44 | 2020 | |
| Rayner Intraocular Lenses Limited | $86.01 | 2025 | Rayner Cataract Set 1, Rayone Emv, Rayone Aspheric |
| Astellas Pharma US INC | $37.08 | 2024-2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $34.89 | 2019-2021 | |
| Eyepoint US, INC. | $33.98 | 2020-2021 | |
| Ocular Therapeutix, INC. | $32.54 | 2019-2024 | Dextenza |
| Omeros Corporation | $20.49 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Lebow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.